| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
CAMBRIDGE, Mass.—In the absence of willing suitors, Biogen Idec's Board of Directors announced the company will continue its present course as an independent company. The announcement follows the completion of a strategic review to seek alternatives to maximize shareholder value that suggested the company look for potential buy-out partners.
 
Ignoring the lack of interest by the industry, the Board suggests that the company's business strategy remains sound and that the company will strive to achieve several strategic goals by year-end 2010, including having more than 40% of revenue coming from international business, launching four new products or new indications, getting six programs into late-stage clinical development, and generating 15% CAGR revenue growth.
 
The news isn't all bad for the company, however, as the decisions to open itself to buy-out talks and then to close ranks caused Biogen Idec's stock price to fluctuate significantly over the last 3 months, jumping from the $65 range to the $82 range in mid-October and from about $75 to less than $60 this past week.

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

GreenCooling

Thermo Scientific™ Centrifuges with GreenCool Technology

Next-generation natural refrigerant cooling system for centrifuges, offering a lower Global Warming Potential and reduced energy consumption.
Clear sample tubes are shown in a clear tote with red lids in a sample prep robot with a blue and silver industrial lab background.

The crucial role of sample preparation in biotherapy manufacturing

Discover how better sample preparation can unlock improved assay accuracy and analytical results.
A black mosquito is shown on pink human skin against a blurred green backdrop.

Discovering deeper insights into malaria research

Malaria continues to drive urgent research worldwide, with new therapies and tools emerging to combat the parasite’s complex lifecycle and global burden.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue